|
As Chief Medical Officer, Dr. Salazar-Grueso is responsible for the medical governance of Solstice Neurosciences� Clinical, Regulatory and Medical Affairs departments. Dr. Salazar-Grueso brings a broad and extensive background in research and development of multiple therapeutic areas spanning more than 20 years in academia and industry. That experience has led him to the research and development of new biologicals, new chemical entities, cell based and gene therapeutics. In addition, he has had responsibility for all aspects of product lifecycle management including preclinical target and lead selection, global clinical/operations development - from phase I to phase III - as well as post-approval clinical marketing support and Medical Affairs. In his previous position as VP & Global Head, Medical Development Group for Specialized Therapeutics with the former Schering AG, Dr. Salazar-Grueso led the international team in the global clinical and operations area, responsible for all aspects of development and marketed products in CNS, CV & GI therapy areas. Prior to Schering, he was the Therapeutic Area Medical Leader with AstraZeneca where he led US and global clinical product development in the CNS Therapy Area. Dr. Salazar-Grueso received his medical degree from Rush Medical College, and his Neurology training at University of Chicago. He is a board-certified Neurologist. | 